🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT06372964
Recruiting Phase 3

Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

NCT06372964 · tracked via the Priya Life Science USA tracker
Sponsor
Intra-Cellular Therapies, Inc.
Phase
Phase 3
Started
2024-05-14
Last updated
2026-08-28

Condition(s) studied

Bipolar Depression

Investigational drug(s) / intervention(s)

LumateperonePlacebo

Lumateperone: Lumateperone administered orally, once daily.

Placebo: Matching placebo administered orally, once daily.

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).

Eligibility

Sex
ALL
Min age
10 Years
Max age
17 Years
Healthy volunteers
No
Inclusion Criteria: 1. Able to provide consent as follows: * The Legally Authorized Representative (LAR) must provide written, informed consent. * The patient must provide written assent; 2. Male or female patients 10 to 17 years of age, inclusive; 3. Have a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) primary diagnosis of bipolar I or bipolar II disorder with a current MDE without psychosis as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL); 4. Subject has a lifetime history of at least one manic or hypomanic episode. 5. Subject's current major depressive episode is ≥ 4 weeks and less than 12 months in duration; 6. CDRS-R total score ≥ 45 with ≥ 5 on Item 11 (depressed feelings) at Screening and Baseline; 7. Young Mania Rating Scale (YMRS) score ≤ 15 (with YMRS Item 1 \[elevated mood\] score ≤ 2) at Screening and Baseline. Exclusion Criteria: 1. Has a primary psychiatric diagnosis other than bipolar I or bipolar II disorder. Exception includes: * Attention deficit hyperactivity disorder (ADHD). If a subject is taking medications for ADHD, they must have been on a stable treatment regimen of these medication(s) for 30 days prior to screening and the treatment regimen is expected to remain stable throughout the study. 2. Intellectual disability based on Investigator opinion and DSM-5 criteria 3. Patient has been hospitalized for a bipolar manic episode within the 30 days prior to randomization; 4. Demonstrates a ≥ 25% decrease (improvement) in the CDRS-R total score between Screening and Baseline visits, or the CDRS-R is below 45 at Baseline; 5. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during his/her participation in the study or 1. At Screening, the patient scores "yes" on Suicidal Ideation Items 3, 4, or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening or, at Baseline, the patient scores "yes" on Suicidal Ideation Items 3, 4, or 5 since the Screening Visit; 2. At Screening, the patient has had 1 or more suicidal attempts within the 2 years prior to Screening; or 3. At Screening or Baseline, scores \> 3 on Item 13 (suicidal ideation) on the CDRS-R; or 4. The patient is considered to be an imminent danger to him/herself or others.

Primary outcome measure(s)

Trial sites (68)

FacilityCityRegionStatus
Harmonex Neuroscience Research Dothan Alabama Recruiting
Pillar Clinical Research, LLC Little Rock Arkansas Recruiting
Advanced Research Center, Inc Anaheim California Recruiting
Inland Psychiatric Medical Group Inc Redlands California Recruiting
UC Davis Health System Sacramento California Recruiting
University of California San Diego Medical Center San Diego California Completed
Next Level Clinical Trials, LLC West Covina California Recruiting
MCB Clinical Research Centers LLC Colorado Springs Colorado Completed
Royal Palm Clinical Research Fort Myers Florida Suspended
United Research Institute Hialeah Florida Completed
Advanced Research Institute of Miami Homestead Florida Suspended
Vital Care Research Miami Florida Suspended
Columbus Clinical Services LLC Miami Florida Suspended
Care Research Center Inc Miami Florida Recruiting
HealthMed Clinical Center Inc Miami Florida Recruiting
Ocean Blue Medical Research Center Inc. Miami Florida Completed
AP Medical Research Miami Florida Suspended
Envision Trials LLC Miami Florida Recruiting
GTL Medical and Research Group Miami Florida Completed
Links Clinical Trials Miami Florida Recruiting
SouthGen Clinical Research LLC Miami Florida Completed
New Med Research Inc Miami Gardens Florida Recruiting
The Angel Medical Research Corporation Miami Gardens Florida Recruiting
Riveldi Biomedical Research Miami Lakes Florida Recruiting
APG Research LLC Orlando Florida Recruiting
Health Synergy Clinical Research West Palm Beach Florida Recruiting
CenExeli Research LLC Atlanta Georgia Recruiting
Advanced Discovery Research Atlanta Georgia Completed
Salveo Integrative Health Inc Lawrenceville Georgia Completed
CenExeli Research LLC 1 Savannah Georgia Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois Recruiting
Revive Research Institute Elgin Illinois Recruiting
Indiana University Indianapolis Indiana Completed
MTP Psychiatry LLC Baltimore Maryland Completed
Neurobehavioral Medicine Group Bloomfield Hills Michigan Recruiting
Midwest Research Group Saint Charles Missouri Recruiting
Washington University School of Medicine Child and Adolescent Psychiatry Clinic St Louis Missouri Completed
Alivation Research LLC Lincoln Nebraska Recruiting
NYU Child Study Center New York New York Recruiting
Haidar Almhana Nieding Avon Lake Ohio Completed

+ 28 more sites — see the full list on the official registry below.

More Intra-Cellular Therapies, Inc. trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06372964 on ClinicalTrials.gov ↗ ← All trials in the USA